Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2, Randomized, Biomarker-driven Clinical Study in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With MCL-1 Dependence ≥30%

NCT02520011 is registered in ClinicalTrials.gov with Sumitomo Pharma America, Inc. as lead sponsor.

NCT NCT02520011
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02520011 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2, Randomized, Biomarker-driven Clinical Study in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With MCL-1 Dependence ≥30%
Lead sponsor
Sumitomo Pharma America, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
March 14, 2016
Completion date
February 12, 2020
Enrollment
104 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia